AVI BioPharma to Hold Third Quarter Results Conference Call On November 12.Business Editors/Health & Medical Writers PORTLAND, Ore.--(BUSINESS WIRE)--Nov. 5, 2001 AVI BioPharma, Inc. ("AVI (Audio Video Interleaved) A Windows multimedia video format from Microsoft. It interleaves standard waveform audio and digital video frames (bitmaps) to provide reduced animation at 15 fps at 160x120x8 resolution. Audio is 11,025Hz, 8-bit samples. ") (Nasdaq:AVII, AVIIW, AVIIZ), a biopharmaceutical company developing products based on cancer immunotherapy and antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). technologies, announced today that the Company will release 2001 third quarter financial results before market open on Monday, November 12, 2001. Denis Denis, king of Portugal: see Diniz. R. Burger, Ph.D., chairman and chief executive officer, and Alan P. Timmins, president and chief operating officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. , will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time on Monday, November 12 to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 800/252-8298. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 800/633-8284 for domestic callers and entering reservation code 19896072. The live conference call also will be available via the Internet at www.avibio.com and a recording of the call will be available on the Company's Website for 14 days following the completion of the call. AVI BioPharma, Inc. develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: cancer immunotherapy and gene-targeted drugs. Its lead clinical agent, AVICINE, a therapeutic cancer vaccine, has completed enrollment in a Phase II trial in pancreatic cancer pancreatic cancer Malignant tumour of the pancreas. Risk factors include smoking, a diet high in fat, exposure to certain industrial products, and diseases such as diabetes and chronic pancreatitis. Pancreatic cancer is more common in men. and is in a Phase III pivotal trial in colorectal cancer. The first application of its NEUGENE compounds, Resten-NG, is designed to treat cancer, cardiovascular restenosis and other cell proliferation disorders by inhibiting the production of a cellular transcription factor, the oncogene oncogene Gene that can cause cancer. It is a sequence of DNA that has been altered or mutated from its original form, the proto-oncogene (see mutation). Proto-oncogenes promote the specialization and division of normal cells. c-myc. It is currently in Phase II trials for restenosis. More information about AVI is available on the Company's Website at www.avibio.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion